Immunotherapy for Colorectal Cancer
The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic populat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/9/5/50 |
| id |
doaj-d166e7d3703a417d8b09156930f4839d |
|---|---|
| record_format |
Article |
| spelling |
doaj-d166e7d3703a417d8b09156930f4839d2020-11-25T00:13:52ZengMDPI AGCancers2072-66942017-05-01955010.3390/cancers9050050cancers9050050Immunotherapy for Colorectal CancerPatrick M. Boland0Wen Wee Ma1Roswell Park Cancer Institute, Department of Medicine, Elm and Carlton St, Buffalo, NY 14263, USAMayo Clinic, Division of Medical Oncology, 200 First St. SW, Rochester, MN 55905, USAThe recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.http://www.mdpi.com/2072-6694/9/5/50colon cancerimmunotherapyanti-PD1 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Patrick M. Boland Wen Wee Ma |
| spellingShingle |
Patrick M. Boland Wen Wee Ma Immunotherapy for Colorectal Cancer Cancers colon cancer immunotherapy anti-PD1 |
| author_facet |
Patrick M. Boland Wen Wee Ma |
| author_sort |
Patrick M. Boland |
| title |
Immunotherapy for Colorectal Cancer |
| title_short |
Immunotherapy for Colorectal Cancer |
| title_full |
Immunotherapy for Colorectal Cancer |
| title_fullStr |
Immunotherapy for Colorectal Cancer |
| title_full_unstemmed |
Immunotherapy for Colorectal Cancer |
| title_sort |
immunotherapy for colorectal cancer |
| publisher |
MDPI AG |
| series |
Cancers |
| issn |
2072-6694 |
| publishDate |
2017-05-01 |
| description |
The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors. |
| topic |
colon cancer immunotherapy anti-PD1 |
| url |
http://www.mdpi.com/2072-6694/9/5/50 |
| work_keys_str_mv |
AT patrickmboland immunotherapyforcolorectalcancer AT wenweema immunotherapyforcolorectalcancer |
| _version_ |
1725392797724311552 |